A new study that is sure to garner attention linked creatine supplementation with increased metastasis of some cancerous tumors. But experts noted that the headline went beyond what the study actually showed.
The new research was made public today as a preprint on the site Nature Communications. It was the work of a research team associated with various institutions in China.
The title of the study said it all, when it comes to the waves that it is sure to create: “Exogenous creatine supplementation promotes tumor metastasis via megakaryocyte creatine kinase B-STAT5B signaling.”
The researchers used a complicated research design to elucidate creatine’s function within platelets and within megakaryocytes (MKs), the large cells in bone marrow that are responsible for platelet production. The researchers noted that perturbations within the MKs are thought to result in the production of platelets whose function could be different in some ways from the norm.
The same research group had previously investigated the roles of glucose metabolism and ketone metabolism within MKs and what that implied for the behavior of the resulting platelets. In this study, their goal was to study the role of creatine in this regard, and to see if higher creatine levels induced MKs to produce platelets that helped cancer cells to more easily travel in the bloodstream to new lodging points, dodging the immune system in the process.
The researchers used several different types of mice in their study. In some cases, the mice — after having been dosed with a clinically relevant amount of creatine monohydrate — had blood drawn from which the platelets isolated . Then in vitro tests were conducted to measure how the platelets bound to cancer cells. The mice also had cancerous cells injected directly into a tail vein for an in vivo test of how well the cells traveled within the bloodstreams of the mice.
The researchers also crossbred races of mice to try to isolate and control for certain genetic factors that were implicated in the cell signaling pathways they were investigating.
“Hyperactive” platelets
The main finding of the mouse portion of the study was that exogenous creatine resulted in the production of “hyperactive” platelets that were “pro-metastatic.”
The study also included an arm with 11 human subjects. The subjects took 20 g/d of creatine monohydrate for two weeks. The main purpose of this portion of the study was to collect some human data along with murine data. The researchers said that this part of study showed that this high creatine does also produced “hyperactive” and “pro-metastatic” platelets in humans.
Platelets from these volunteers were then injected into immunodeficient mice, which resulted in the same boost in metastasis as observed in the earlier, mouse-only portion of the study.
In addition to the cell-level findings, the authors also noted that their findings could change the recommendations for creatine supplementation for cancer patients. Exercise is often recommended for these patients, but using creatine to boost performance might not be the best idea.
Experts: Paper adds to knowledge base, but claims to show more than it does
Susan Hewlings, Ph.D., principal in the consulting firm Substantiation Sciences, expressed some reservations. For one, she said the mechanistic models the authors used in their mice were “forced” metastasis. Cancer cells were injected directly into the bloodstreams of the mice, which is not how metastasis actually works.
In addition, she noted that the human data was from healthy young subjects, who are possibly not representative of older people who are more likely to be cancer sufferers. And the 20 g/d dosage for two weeks is well beyond what is commonly recommended; a dosage that high typically is only used for three to five days before backing off to a maintenance dose of 3 g/d to 5 g/d.
“To say creatine causes tumor growth is a huge stretch and it goes against a large existing safety record. The International Society of Sports Nutrition’s 2017 position stand and multiple systematic reviews (both cited in this paper) support creatine’s safety in healthy adults across years of use. A single mechanistic pathway paper — however well done in the lab world — doesn’t overturn or even counter that body of evidence,” she said.
Wayne Heidenreich, M.D., former chief medical officer of Northwestern Mutual Life Insurance Co., concurred, saying the paper might be misconstrued in some circles, but nevertheless it could offer some insights to clinicians.
“There is no evidence that creatine causes cancer. In fact, it may help protect one from the development of a primary tumor. Clinical studies have not proven an increase in the frequency of metastatic disease in humans,” he maintained.
“I would caution against use if someone had a history of primary cancer, e.g., breast cancer, colon cancer and prostate cancer, etc. I would use the disclosure of using creatine as an opportunity to reinforce diligent cancer screening per clinical recommendations for anyone using creatine (again, e.g., mammograms, colonoscopy, prostate cancer screening, etc.),” Heidenreich added.